NMN Established as Safe in First Human Trials
In November 2019, the results of the first human study of Nicotinamide Mononucleotide (NMN) were published. The study was conducted at the Clinical Trial Unit, Keio University School of Medicine, Japan and included a total sample of 10 healthy Japanese men between the ages of 40 and 60 years old. Subjects received a single dose of 100, 250, or 500 mg NMN capsules. Ultimately, among the sample group, there were no adverse effects and the trial was able to establish NMN’s general safety in humans.
The study measured subjects’ responses to NMN by analyzing their respective heart rates, blood pressures, oxygen saturations, body temperatures, neurological reactions, and metabolic reactions via blood and urine samples. Among all subjects, at all dosage levels, NMN was effectively metabolized and no adverse effects were found. Unlike Nicotinamide (NAM), another NAD+ precursor, NMN did not induce any forms of nausea or flushing when taken in high doses. Nor did NMN cause any hepatoxicity, chemical-driven liver damage, that Nicotinamide (NAM) has been reported to induce.
As stated in the study, “The single oral administration of NMN was safe and effectively metabolized in healthy men without causing any significant deleterious effects. Thus, the oral administration of NMN was found to be feasible, implicating a potential therapeutic strategy to mitigate aging-related disorders in humans.”
Next Steps: Further Studies
With the general safety of oral NMN being established, more robust testing is currently being and will continue to be performed to further assess the efficacy and safety of NMN. These new studies are testing the safety and efficacy of NMN on a more robust level by examining more diverse sample groups, larger sample sizes, higher dose NMN treatments, new KPIs, and more.
References: Irie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., . . . Itoh, H. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153-160. doi:10.1507/endocrj.ej19-0313